Pricing and reimbursement frameworks in Central Eastern Europe: A decision tool to support choices

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 15, Issue 1, 2015, Pages 145-155

  Kolasa, Katarzyna ^a   Kalo, Zoltan ^b   Hornby, Edward ^c  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^c H Labs Ltd   (United Kingdom)

Author keywords

budget impact; Central Eastern European region; cost effectiveness; innovative pricing and reimbursement schemes

Indexed keywords

ARTICLE; CENTRAL EASTERN EUROPE; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DRUG INDUSTRY; DRUG RESEARCH; EUROPE; FEASIBILITY STUDY; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE QUALITY; HUMAN; OUTCOME ASSESSMENT; PATIENT ADVOCACY; PATIENT RIGHT; PILOT STUDY; REIMBURSEMENT; SYSTEMATIC REVIEW; COST; COST BENEFIT ANALYSIS; DECISION MAKING; EASTERN EUROPE; ECONOMICS; HEALTH CARE DELIVERY;

COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DECISION MAKING; DECISION TREES; DRUG INDUSTRY; EUROPE, EASTERN; HEALTH SERVICES ACCESSIBILITY; HUMANS; REIMBURSEMENT MECHANISMS;

EID: 84936988478     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2014.898566     Document Type: Article

References (51)

1. European Multiple Sclerosis Platform. MS Barometer (2011). Available from: www. emsp.org/attachments/article/160/MS-Barometer-2011.pdf [Last accessed 30 august 2012
2. Kobelt G, Kasteng F. Access to innovative treatments in rheumatoid arthritis in Europe: a report prepared for the European Federation of pharmaceutical industry associates (EFPIA) (2009). Available from: www.comparatorreports.se/Access%20to%20MS%20treatments%20-%20October%202009.pdf [Last accessed 18 October 2013
3. Towse A. Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?. Br J Clin Pharmacol 2010;70(3):360-6
4. Carlson J, Sullivan S, Garrison L, et al. Linking payment to health outcomes: a taxonomy and examination of performancebased reimbursement schemes between healthcare payers and manufacturers. Health Policy 2010;96(3):179-90
5. Garrison LP Jr, Towse A, Briggs A, et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health 2013;16(50):703-19
6. Hammerman A, Feder-Bubis P, Greenberg D. Financial risk-sharing in updating the National List of Health Services in Israel: stakeholders' perceive interests. Value Health 2012;15(5):737-42
7. Vogler S, Zimmermann N, Habl C, et al. Discounts and rebates granted to public payers for medicines in European countries. South Med Rev 2012;5(1):38-46
8. de Pouvourville G. Risk-sharing agreements for innovative drugs: a new solution to old problems?. Eur J Health Econ 2006;7(3):155-7
9. Kaló Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res 2013; 13(6):735-41
10. Ridley DB. Price differentiation and transparency in the global pharmaceutical marketplace. Pharmacoeconomics 2005; 23(7):651-8
11. SJEM. Act of 12 May 2011 on the refund of medicines, foodstuffs for particular nutritional uses and for medical devices [article in Polish] (2011). Available from: http://isap.sejm.gov.pl/DetailsServlet?. id=WDU20111220696 [Last accessed 19 October 2013
12. Vienonen MA, Wlodarczyk WC. Health care reforms on the European scene: evolution, revolution or seesaw?. World Health Stat Q 1993;46(3):166-9
13. Sowada C. Health systems in the CEE accession states. In: Lutz W, Richter R, Wilson Chr, editors. The new generations of Europeans: demography and families in the enlarged European Union (population and sustainable development). Earthscan; London, UK: 2006. p. 288
14. Kaló Z, Bodrogi J, Boncz I, et al. Capacity Building for HTA implementation in middle-income countries: the case of Hungary. Value in Health Regional Issues 2013;2(2):264-6
15. Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing or patient access scheme?. A framework for coverage decisions. Value Health 2012;15(3):570-9
16. Stafinski T, McCabe CJ, Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics 2010;28(2):113-42
17. Adamski J, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res 2010;10:153
18. Claxton K, Palmer S, Longworth L, et al. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development. Health Technol Assess 2012;16(46):1-323
19. Green C, Bryant J, Takeda A, et al. Bortezomib for the treatment of multiple myeloma patients. Health Technol Assess 2009;13(Suppl 1):29-33
20. National Institute for Health and Clinical Excellence. Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (2009). Available from: http://publications.nice.org.uk/sunitinib-forthe-first-line-treatment-of-Advanced-Andormetastatic-renal-cell-carcinoma-ta169 [Last accessed 18 October 2013
21. Pickin M, Cooper C, Chater T, et al. The multiple sclerosis risk sharing scheme monitoring study -early results and lessons for the future. BMC Neurology 2009;9:1
22. Raftery J. Multiple sclerosis risk sharing scheme: a costly failure. BMJ 2010;340: c1672
23. Møldrup C. No cure, no pay. BMJ 2005; 330(7502):1262-4
24. Kolasa K, Wasiak R. Health technology assessment in Poland and Scotland: comparison of process and decisions. Int J Technol Assess Health Care 2012;28(1): 70-6
25. Willis M, Persson U, Zoellner Y, Gradl B. Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa) in Sweden. Appl Health Econ Health Policy 2010;8(6): 377-86
26. Jaroslawski S, Toumi M. Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. BMC Health Serv Res 2011;11:259
27. National Institute for Health and Clinical Excellence. Ranibizumab and pegaptanib for treatment of age-related macular degeneration (2008; revised 2012). Available from: www.nice.org.uk/nicemedia/live/12057/41719/41719.pdf [Last accessed 18 October 2013
28. Mills J. NICE set to recommend Stelara for psoriasis. SCRIP Intelligence (17 August 2009). Available from: www. scripintelligence.com/policyregulation/NICE-set-to-recommend-Stelara-forpsoriasis-173593 [Last accessed 19 October 2013
29. Health Consumer Powerhouse, The Empowerment of the European Patient 2009 -options and implications. Available from: www.healthpowerhouse.com/files/EPEI-2009/european-patient-empowerment-2009-report.pdf [Last accessed 19 October 2013
30. Project Group on facilitating supply in small markets. Available from: http://ec. europa.eu/enterprise/sectors/healthcare/files/docs/smallmarkets-positionpaper-en.pdf [Last accessed 10 December 2013
31. Lu C, Williams K, Day R, et al. Access to high cost drugs in Australia. BMJ 2004; 329(7463):415-16
32. Rutten F, Uyl-de Groot C, Vulto A. Innovative payment systems for medicines in Europe. EJHP Pract 2009;15:60-2
33. Towse A, Garrison LP Jr. Can't get no satisfaction?. Will pay for performance help?: toward an economic framework for understanding performance-based risksharing agreements for innovative medical products. Pharmacoeconomics 2010;28(2): 93-102
34. Sparrowhawk K. Commentary: NICE shares risk with the drug industry. SCRIP Intelligence (5 September 2007). Available from: www.scripintelligence.com/home/news/Commentary-NICE-National-Institute-for-health-And-Clinical-Excellenceshares-risk-with-The-drug-industry-by-Keiron-Sparrowhawk-of-Pricespective-36430 [Last accessed 19 October 2013
35. Wagstaff A. Health rationing in Europe: can cancer get a fair hearing?. Cancer World (2009). Available from: www.cancerworld. org/Articles/Issues/30/May-June-2009/Drug-Watch/33/Health-rationing-in-Europe-cancancer-get-A-fair-hearing-.html [Last accessed 19 October 2013
36. National Institute for Health and Clinical Excellence. Rituximab for aggressive non-Hodgkin's lymphoma (2003). Available from: www.nice.org.uk/nicemedia/live/11506/32679/32679.pdf [Last accessed 19 October 2013
37. National Institute for Health and Clinical Excellence. National Collaborating Centre for Women's and Children's Health. Diagnosis and management of type 1 diabetes in children and young people (2004). Available from: www.nice. org.uk/nicemedia/pdf/CG015childrenfullguideline.pdf [Last accessed 19 October 2013
38. Thomson D. British oncology pharmacy association: position statement on risk sharing schemes in oncology (March 2008). Available from: www.bopawebsite. org/contentimages/publications/Position-Statement-on-Risk-Sharing- ProgrammesFINAL-2-.pdf [Last accessed 19 October 2013
39. Gajraj E, Chung H, Boysen M, et al. 2009; Lenalidomide for the treatment of relapsed multiple myeloma. Lancet 2009;10(7):647-8
40. Shearer L. CIGNA and Merck sign performance-based contract (23 April 2009). Available from: http://newsroom.cigna.com/article-display.cfm?article-id=1043 [Last accessed 19 October 2013
41. Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing remitting multiple sclerosis. J Manag Care Pharm 2009;15(7): 543-55
42. Lilford RJ. MS risk sharing scheme. Response from chair of scientific advisory committee. BMJ 2010;341:c3590
43. Richards RG. MS risk sharing scheme. Some clarification needed. BMJ 2010;341: c3589
44. Messori A. MS risk sharing scheme. Outcome based schemes are more common than you think. BMJ 2010;341:c3588
45. Scolding N. The multiple sclerosis risk sharing scheme. BMJ 2010;340:c2882
46. McCabe C, Chilcott J, Claxton K, et al. Continuing the multiple sclerosis risk sharing scheme is unjustified. BMJ 2010;340:c1786
47. Boggild M, Palace J, Barton P, et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ 2009;339:b4677
48. Sudlow CL, Counsell CE. Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. BMJ 2003;326(7385):388-92
49. Chalkidou K. Only in research: a polite no or a valuable policy option?. (2006). Available from: www.healthlinks-events.co. uk/nice2006/h11a-thu-1145-chalkidou.pdf [Last accessed 19 October 2013
50. Gallo PF, Deambrosis P. Pharmaceutical risk-sharing and conditional reimbursement in Italy (2008). Available from: www. ceestahc.org/pliki/symp2008/gallo.pdf [Last accessed 19 October 2013
51. Persson U, Willis M, Odegaard K. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden. Eur J Health Econ 2010;11(2):195-203